ELAB Company Profile and Key Details

PMGC Holdings Inc. has 424.24 thousand shares outstanding. The public float is 391.07 thousand shares, elevated short interest at 1.79% of float. This equals 26.55 thousand shares. The short ratio is 1.52 days. Institutional investors hold 2.5% of the float. Insiders own 11.41%. KARP DOUGLAS M holds 0.00 shares, PATTERSON MARK R has 0.00 shares and GRANSEE DAVID H has 0.00 shares.

ELAB has shown weak momentum, losing -47.79% over the past week and -64.3% over the past quarter, though year-to-date performance is down -96.42%. Short-term trend indicators are bullishly aligned (SMA20 -51.75%, SMA50 -61.62%, SMA200 -74.3%). The stock’s 14-day RSI is 15.58 (weak momentum), while the ATR of 0.48 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -97.98% below its high and over -1.95% above its low. Average 10-day trading volume of 2.29 million shares is significantly above the 3-month average of 689.35 thousand, indicating heightened recent market interest.

PMGC Holdings Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.50. This means the shares are trading above this model’s fair value.

PMGC Holdings Inc. (NASDAQ:ELAB) closed at $1.70 USD, losing -$0.31 (-15.62%) from the previous close of $2.01. The stock is currently within 5% of its 52-week low $1.62 and $99.96. With a market capitalization of about $719.49 thousand, PMGC Holdings Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.30). Key stats such as the average daily volume over the past year has been around 745.95 thousand shares, volume is running light vs its 52-week average. Headquartered in Newport Beach, CA, PMGC Holdings Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Graydon Bensler, the company employs approximately 2 people and listed since November 21, 2023. PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products.

PMGC Holdings Inc. trades at a P/E ratio of -0.27, slightly below the S&P 500 average, with a price-to-sales ratio of -0.68 and a price-to-book ratio of 0.13 suggesting the stock is closer to book value. The P/FCF stands at -0.38, also above market averages.

PMGC Holdings Inc. (NASDAQ:ELAB) shares are down -96.42% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows PMGC Holdings Inc. trading at a premium to the broader market with a P/E of -0.27. Our AI forecast model points to short-term weakness (-28.36% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that PMGC Holdings Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -28.36%, with price expected at $1.44 by January 05, 2026, within a range of $0.88 to $2.04 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by March 19, 2026, with a range of $0.00 to $25.79. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by December 22, 2026, within a range of $0.00 to $87.84.